However, epithelial cancers — such as bladder cancer — also exhibit deregulation and mutation of FGFR3, but whether this contributes to tumorigenesis in vivo has remained unclear. To address ...

He told the meeting that in patients with metastatic bladder cancer with FGFR3 mutations, whose cancer had progressed on previous treatments, he and his colleagues saw positive results regarding ...

Bladder cancer can be broadly divided into two basic ... Furthermore, CIS-associated chromosome changes and FGFR3 mutations (a known marker of papillary cancers) were found to be mutually exclusive.

Around 20 percent of people with advanced or metastatic bladder cancer have FGFR3 alterations, which can drive the growth of cancer cells. Erdafitinib is a once-daily, oral FGFR kinase inhibitor ...

Balversa represents a promising advancement for the treatment of metastatic bladder cancer with FGFR3 or FGFR2 alterations, as it offers a personalized and effective option for patients who have ...

Patients with advanced bladder cancer that has spread to other parts ... The drug targets changes in the FGFR3 gene ... Final results from the SWOG S1011 randomized Phase III clinical trial ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months. On Nov. 6, 2024, ...

10,500 people in the UK are diagnosed with bladder cancer every year [1] Erdafitinib is a once-daily, oral FGFR kinase inhibitor, which works by inhibiting the activity of FGFR3 alterations in cancer ...

Around 10,500 people are diagnosed with bladder cancer annually in the UK, with approximately 20% of those having FGFR3 genetic alterations driving cancer growth. Professor Alison Birtle of Lancashire ...